Weekly Funding Opportunities

[Med Research]

NIH and NSF Coronavirus Websites for the Research Community

NIH:   https://urldefense.com/v3/__https://grants.nih.gov/grants/natural_disasters/corona-virus.htm__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvwc8T8io$ 
NSF:   https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/coronavirus/__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvUx8-TbM$ 

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-030.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGveYRzQl4$ >
NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.
NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:

  *   Studies to identify optimal 2019-nCoV in vitro culture requirements and conditions;
  *   Development of reagents and assays for virus characterization;
  *   Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
  *   Studies to identify viral epitopes critical for binding neutralization;
  *   Studies to examine virus stability and persistence;
  *   Production of molecular clones of 2019-nCoV, reporter viruses and recombinant viral proteins;
  *   Development of animal models of 2019-nCoV infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
  *   Studies on the evolution and emergence of 2019-nCoV viruses including the identification of factors that affect viral host-range and virulence;
  *   Virologic and serologic surveillance studies of the distribution and natural history of 2019-nCoV viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
  *   Development of sensitive, specific, and rapid clinical diagnostic tests for 2019-nCoV;
  *   Development of 2019-nCoV therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of 2019-nCoV antiviral activity of existing or candidate therapeutics initially developed for other indications;
  *   Identification and evaluation of the innate, cellular and humoral immune responses to 2019-nCoV infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to 2019-nCoV and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
  *   Development of 2019-nCoV vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.
NIGMS Interests

  *   Incorporation of data related to the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of coronaviruses and related infectious agents.
Expires February 6, 2021. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.

Division of Integrative Organismal Systems Core Programs and Rules of Life<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2020/nsf20536/nsf20536.htm__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvakaHUyo$ >
The Division of Integrative Organismal Systems (IOS) Core Programs Track supports research aimed at understanding why organisms are structured the way they are and function as they do. Proposals are welcomed in all of the core scientific program areas supported by the Division of Integrative Organismal Systems (IOS). Areas of inquiry include, but are not limited to, developmental biology and the evolution of developmental processes, nervous system development, structure, modification, function, and evolution; biomechanics and functional morphology, physiological processes, symbioses and microbial interactions, interactions of organisms with biotic and abiotic environments, plant and animal genomics, and animal behavior. Proposals should focus on organisms as a fundamental unit of biological organization. Principal Investigators (PIs) are encouraged to apply systems approaches that will lead to conceptual and theoretical insights and predictions about emergent organismal properties.
The four clusters in IOS which are participating in submissions to this solicitation are:
Behavioral Systems Cluster<https://urldefense.com/v3/__https://nsf.gov/funding/pgm_summ.jsp?pims_id=504676&org=IOS&from=home__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvfe0qTBI$ >: The Behavioral Systems cluster contains the Animal Behavior Program.
Developmental Systems Cluster<https://urldefense.com/v3/__https://nsf.gov/funding/pgm_summ.jsp?pims_id=504677&org=IOS&from=home__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvHhRxHbU$ >: Programs within the Developmental Systems Cluster are: the Plant, Fungal and Microbial Developmental Mechanisms Program, the Animal Developmental Mechanisms Program and the Evolution of Developmental Mechanisms Program.
Neural Systems Cluster<https://urldefense.com/v3/__https://nsf.gov/funding/pgm_summ.jsp?pims_id=504678&org=IOS&from=home__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvtTKWKPE$ >: Programs within the Neural Systems Cluster are the Organization Program, the Activation Program and the Modulation Program.
Physiological and Structural Systems Cluster<https://urldefense.com/v3/__https://nsf.gov/funding/pgm_summ.jsp?pims_id=504679&org=IOS&from=home__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvbNXy-i4$ >: Programs within the Physiological and Structural Systems Cluster are: the Symbiosis, Defense and Self-recognition Program (SDS), the Physiological Mechanisms and Biomechanics Program (PMB), the Integrative Ecological Physiology Program (IEP) and the NSF-NIFA Plant Biotic Interactions Program (PBI).
The Rules of Life Track supports integrative proposals that span the subcellular and cellular scales normally funded by MCB to the organ, tissue, organismal, and group scale typically funded by IOS, to population, species, community and ecosystem scales typically funded by DEB. Rules of Life proposals may also include enabling infrastructure through joint submission with DBI. Discovery of fundamental principles and enabling infrastructure will advance understanding and further predict how key properties of living systems emerge from the interaction of genomes, phenotypes, and developmental, social and environmental context across space and time. This track provides opportunities to advance understanding of the Rules of Life by new mechanisms for review and funding of proposals that span two or more divisions in the Biological Sciences Directorate.
Applications welcome anytime. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.

Foundation for Women’s Wellness Research Awards<https://urldefense.com/v3/__http://thefww.org/research-awards/__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvAZfk5os$ >
FWW Research Awards target small, short-term studies with promise for improving medical care in leading women’s health concerns including cardiovascular disease, female cancers, the role of hormones in disease and stage-of-life health issues like pregnancy and menopause and diseases disproportionately affecting women. WW Research Awards are one-time, non-recurring $25,000.
Due April 6, 2020. Med-RA deadline to receive draft documents: March 24.

WITH Foundation: Healthcare for Adults with Developmental Disabilities<https://urldefense.com/v3/__https://withfoundation.org/grant-guidelines/__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvkj8S0u8$ >
The WITH Foundation is inviting letters of intent from organizations for efforts to promote comprehensive health care for adults with developmental disabilities. Grants will be awarded in support of programs that improve delivery of health care to adult consumers with developmental disabilities that include at least one of the following facets: improve health practitioner competency through education and/or training programs; address the current inadequate reimbursement system; advance formal care coordination; enhance public awareness regarding the inadequacies of developmentally disabled care in order to advance systemic change; increase understanding of supported decision-making in healthcare settings; national efforts in digital health that support designers and developers to include the perspectives/experiences of the IDD community within the design process in order to create better technology for all; social policy research; and identify and overcome barriers to high-quality healthcare access. The foundation typically provides a year of support, of usually between $30,000 and $50,000, but may cover as much as three years to support programming that warrants extended funding.
Letter of intent due April 16, 2020. Med-RA deadline to receive draft documents: April 6.

Congressionally Directed Medical Research Programs
Bone Marrow Failure Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/bmfrp__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvAFgbI3o$ >
Idea Development Award
Pre-application (preproposal): May 11, 2020. Application: August 5, 2020.
Med-RA deadline to receive draft documents for May 11, 2020 preproposal deadline: April 28.
Lung Cancer Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/lcrp__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvCqYIokE$ >
Concept Award
Pre-application (required letter of intent): May 27, 2020. Invited full application: June 10, 2020.
Med-RA deadline to receive draft documents for May 27 letter of intent deadline: May 13.
Idea Development Award
Pre-application (preproposal): May 6, 2020. Invited full application: July 29, 2020.
Investigator-Initiated Translational Research Award
Pre-application (preproposal): May 6, 2020. Invited full application: July 29, 2020.
Med-RA deadline to receive draft documents for May 6, 2020 preproposal deadline: April 23.

Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-139.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvCGUC9G4$ >
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs (NIA or NIAID). Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.
Due May 13, 2020; September 13, 2020; January 13, 2021; May 13, 2021; September 13, 2021; January 13, 2022; May 13, 2022; September 13, 2022; and January 13, 2023. Med-RA deadline to receive draft documents for May 13, 2020 preproposal deadline: April 30.

In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-137.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvuRssnes$ >
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.
Due June 5, 2020; October 5, 2020; June 5, 2021; October 5, 2021; June 5, 2022; and October 5, 2022. Med-RA deadline to receive draft documents for June 5, 2020 deadline: May 26.

Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-131.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGv1yrSjgs$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.

Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-028.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvp3clw0w$ >
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
Due June 29, 2020. Med-RA deadline to receive draft documents: June 16.

Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61 / R33 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-015.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGv28oE830$ >
The objective of this Funding Opportunity Announcement (FOA) is to pair Bioengineers and Immunologists to leverage emerging innovative knowledge in physical and computational sciences for the design and development of an HIV-1 vaccine.
Due July 28, 2020. Med-RA deadline to receive draft documents: July 15.

Alzheimer’s Disease Research Centers (P30 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-019.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvb8vtgYU$ >
This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers (ADRCs). NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.
Due September 15, 2020. Med-RA deadline to receive draft documents: September 1.

Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age (U19 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-015.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvtIa0L_o$ >
This Funding Opportunity Announcement (FOA) invites applications to establish a network to identify, evaluate, track, and conduct research across multiple sites on older adults with superior cognitive performance for their age ("cognitive super agers"). The activity would support aggregation of sufficient numbers of these individuals to advance the field’s understanding of factors that promote sustained cognitive health and those that are not of primary importance. Uniform identification and uniform data collection will allow the study of the behavioral, neurological, health, genetic, environmental, and lifestyle profiles that lead to sustained cognitive and brain function in advanced age. Where extant data exists, harmonization protocols would need to be developed in order to make use of all currently available data. Provision of protocols to obtain brain tissue at autopsy would be an important component.
Due October 1, 2020. Med-RA deadline to receive draft documents: September 21.

Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (R35 – Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-117.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvPuQbfQo$ >
The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's<https://urldefense.com/v3/__https://grants.nih.gov/policy/new_investigators/index.htm__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvHtR0dpA$ > laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS<https://urldefense.com/v3/__https://www.nigms.nih.gov/about/overview/pages/default.aspx__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvEv0SyL0$ >. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will:

  *   Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers.
  *   Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries.
  *   Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively.
  *   Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies.
  *   More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs.
  *   Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research.
  *   Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.
Due October 2, 2020; October 4, 2021; and October 3, 2022. Med-RA deadline to receive draft documents for October 2, 2020 deadline: September 21.

Central and Peripheral Control of Balance in Older Adults (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-011.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvMabm-wY$ >
This Funding Opportunity Announcement (FOA) invites applications that propose basic and/or clinical studies to investigate central and peripheral control of balance in older adults and/or in relevant animal models. This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults.
Due October 2, 2020. Med-RA deadline to receive draft documents: September 21.

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-001.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGv9dx0axs$ >
The purpose of this funding opportunity announcement (FOA) is to fund well-controlled studies in support of a new indication or change in labeling of products to address unmet needs in rare diseases or conditions. Through the funding of efficient and innovative clinical studies evaluating safety and/or efficacy, FDA expects to increase the number of treatments for rare diseases with an unmet medical need and exert a broad and positive impact on rare disease drug development.
Due October 6, 2020 and October 5, 2021. Med-RA deadline to receive draft documents for October 6, 2020 deadline: September 23.

New/Unconventional Animal Models of Alzheimer’s Disease (R24 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-003.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvcqbEdZE$ >
This funding opportunity announcement (FOA) invites research to develop, characterize, and validate new, unconventional, or innovative non-rodent mammalian models of late-onset (sporadic) Alzheimer's Disease (AD). These new models are expected to recapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive hallmarks and aspects of late-onset AD. Research supported under this FOA is expected to provide new investigative tools to identify the gaps in current knowledge related to molecular mechanisms of late-onset AD and identify potential therapeutic targets.
Due October 7, 2020. Med-RA deadline to receive draft documents: September 24.

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 / R01 Clinical Trial Optional)
R34<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-506.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGv1mboWKs$ >
The purpose of this Funding Opportunity Announcement (FOA) is to encourage practice-based research aimed at refining and pilot testing developmentally-focused, theory-based efficacious prevention interventions that may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities.
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-505.html__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvZAR-NeA$ >
The purpose of this FOA is to encourage practice-based research aimed at testing the effectiveness of developmentally-focused theory-based efficacious prevention interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. This FOA seeks to support clinical trials to establish the effectiveness of scalable prevention interventions when implemented using available resources within pediatric-serving primary care settings.
Due October 15, 2020. Med-RA deadline to receive draft documents: October 5.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200316/3d1a00d3/attachment.html>